Skip to main content
. 2019 Feb 28;3:4. doi: 10.1186/s41927-019-0053-z

Table 1.

Clinical and laboratory characteristics of adult cohort

AOSD Control group
Number 30 65
Mean Age (SD; Range) 39 (±16.9; 19–72) 50.9 (±13.5; 23–81)
Sex (male:female) 4:1 1.5:1
Swollen joints per patient* n (Range) 0 (0–16) 0 (0–23)
Patients with swollen joints n (%) 12 (40) 17 (26)
Tender joints per patient* n (Range) 1 (0–24) 0 (0–36)
Patients with tender joints n (%) 17 (57) 31 (48)
Arthralgia n (%) 21 (70) 40 (62)
Erosive arthritis n 3 3
Fever n (%) 20 (66) 31 (48)
Rash n (%) 13 (43) 4 (6,2)
Pharyngitis/sore throat n (%) 8 (27) 4 (6,2)
Splenomegaly n (%) 6 (20) 3 (4,6)
Lymphadenopathy n (%) 2 (6.7) 1 (1,5)
Serositis (Pleuritis/Pericarditis/Peritonitis) n (%) 3 (10) 4 (6,2)
Prednisolone Therapy at IL-18 determination n (%) 15 (50) 24 (37)
DMARD Therapy 11 (37) 16 (25)
WBC > 10,000/ml n (%) 11 (37) 22 (34)
WBC Gpt/ml (SD; Range) 11.7 (± 8.6; 3.9–46.5) 9.4 (± 4.1; 2.3–21.5)
Neutrophils > 80% n (%) 11 (37) 13 (20)
ANA > 1:160 n (%) 3 (10) 6 (0.09)
Elevated ALAT or ASAT n (%) 9 (30) 17 (26)
ALAT μmol/ls (SD) 0.83 (±0.96; 0.23–4.99) 0.73 (±0.63; 0.1–4.8)
RF positive n (%) 1 (0.03) 13 (20)
CRP mg/l (SD; Range) 76.3 (±71.5; < 5–231.7) 45.5 (±62.3; < 5–220)
ESR mm/1 h (SD; Range) 45.0 (±30.1; 1–95) 46.7 (±37.5; 2–150)
RBC Tpt/l (SD; Range) 4.29 (±0.57; 3.18–5.29) 4.37 (±0.95; 2.25–9.6)
Hemoglobin mmol/l (SD; Range) 7.7 (±1.1; 5.6–10) 7.8 (±1.2; 4.3–10)
Hematocrit % (SD; Range) 0.37 (±0.05;0.27–0.46) 0.38 (±0.05;0.21–0.48)
Platelets Gpt/l (SD; Range) 310 (±115.3; 126–624) 326 (±115.4; 83–621)
IL-18 pg/ml* (Range) 10,425 (100–408,000) 355 (87.2–6600)

*Median; SD Standard Deviation, n number, DMARD disease modifying antirheumatic drug, WBC white blood cell count, ANA antinuclear antibodies, ALT alanine transaminase, AST aspartate transaminase, RF rheumatoid factor, CRP C-reactive protein, ESR erythrocyte sedimentation rate, RBC red blood cell count